Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Hospital Acquired Pneumonia (HAP)-Pipeline Review, H1 2015

Hospital Acquired Pneumonia (HAP)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Hospital Acquired Pneumonia (HAP)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Hospital Acquired Pneumonia (HAP)-Pipeline Review, H1 2015', provides an overview of the Hospital Acquired Pneumonia (HAP)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hospital Acquired Pneumonia (HAP), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hospital Acquired Pneumonia (HAP) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Hospital Acquired Pneumonia (HAP)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Hospital Acquired Pneumonia (HAP) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Hospital Acquired Pneumonia (HAP) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Hospital Acquired Pneumonia (HAP) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Hospital Acquired Pneumonia (HAP)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Hospital Acquired Pneumonia (HAP) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Hospital Acquired Pneumonia (HAP) Overview 8

Therapeutics Development 9

Pipeline Products for Hospital Acquired Pneumonia (HAP)-Overview 9

Pipeline Products for Hospital Acquired Pneumonia (HAP)-Comparative Analysis 10

Hospital Acquired Pneumonia (HAP)-Therapeutics under Development by Companies 11

Hospital Acquired Pneumonia (HAP)-Therapeutics under Investigation by Universities/Institutes 13

Hospital Acquired Pneumonia (HAP)-Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Unknown Stage Products 17

Hospital Acquired Pneumonia (HAP)-Products under Development by Companies 18

Hospital Acquired Pneumonia (HAP)-Products under Investigation by Universities/Institutes 20

Hospital Acquired Pneumonia (HAP)-Companies Involved in Therapeutics Development 21

Achaogen Inc. 21

Adenium Biotech ApS 22

AstraZeneca PLC 23

Cardeas Pharma Corp. 24

Cubist Pharmaceuticals, Inc. 25

Dong-A Socio Group 26

F. Hoffmann-La Roche Ltd. 27

KaloBios Pharmaceuticals, Inc. 28

MedImmune, LLC 29

Meiji Seika Pharma Co., Ltd. 30

Melinta Therapeutics, Inc 31

Nabriva Therapeutics AG 32

Savara Inc. 33

Serendex Pharmaceuticals A/S 34

Tetraphase Pharmaceuticals Inc. 35

Hospital Acquired Pneumonia (HAP)-Therapeutics Assessment 36

Assessment by Monotherapy Products 36

Assessment by Combination Products 37

Assessment by Target 38

Assessment by Mechanism of Action 40

Assessment by Route of Administration 42

Assessment by Molecule Type 44

Drug Profiles 46

(amikacin + fosfomycin)-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

(ceftazidime + avibactam sodium)-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

(ceftolozane sulfate + tazobactam sodium)-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

AA-139-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

arbekacin-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

delafloxacin-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

eravacycline-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

fosfomycin-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

KB-001A-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

lefamulin-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

MEDI-3902-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

MEDI-4893-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

molgramostim-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

Nu-2-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

plazomicin sulfate-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

pseudomonas aeruginosa vaccine-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

pseudomonas and VAP conjugate vaccine-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

Qn-2251-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

RG-7929-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

tedizolid phosphate-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

vancomycin hydrochloride-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

Hospital Acquired Pneumonia (HAP)-Recent Pipeline Updates 81

Hospital Acquired Pneumonia (HAP)-Dormant Projects 105

Hospital Acquired Pneumonia (HAP)-Discontinued Products 106

Hospital Acquired Pneumonia (HAP)-Product Development Milestones 107

Featured News & Press Releases 107

Jan 08, 2015: Achaogen Announces Plazomicin Granted QIDP Designation by FDA 107

Oct 03, 2013: Tetraphase to Present New Data at IDWeek on Eravacycline's Potential Activity in Treating Serious Respiratory Infections 107

Sep 06, 2013: Trius Therapeutics to Present Data From Antibiotics Development Programs at ICAAC 2013 108

May 07, 2013: Cubist's Late-stage Antibiotic Candidate CXA-201 Receives FDA Fast Track Designation 110

May 07, 2013: Cubist's Late-stage Antibiotic Candidate CXA-201 Receives FDA Fast Track Designation 110

Jan 07, 2013: Trius Therapeutics's Tedizolid Receives Qualified Infectious Disease Product Designation From FDA 111

Dec 06, 2012: Cubist Pharma's Antibiotic Candidate Ceftolozane Obtains QIDP Designation From FDA 111

Appendix 113

Methodology 113

Coverage 113

Secondary Research 113

Primary Research 113

Expert Panel Validation 113

Contact Us 113

Disclaimer 114

List of Tables

Number of Products under Development for Hospital Acquired Pneumonia (HAP), H1 2015 9

Number of Products under Development for Hospital Acquired Pneumonia (HAP)-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 12

Number of Products under Investigation by Universities/Institutes, H1 2015 13

Comparative Analysis by Late Stage Development, H1 2015 14

Comparative Analysis by Clinical Stage Development, H1 2015 15

Comparative Analysis by Early Stage Development, H1 2015 16

Comparative Analysis by Unknown Stage Development, H1 2015 17

Products under Development by Companies, H1 2015 18

Products under Development by Companies, H1 2015 (Contd..1) 19

Products under Investigation by Universities/Institutes, H1 2015 20

Hospital Acquired Pneumonia (HAP)-Pipeline by Achaogen Inc., H1 2015 21

Hospital Acquired Pneumonia (HAP)-Pipeline by Adenium Biotech ApS, H1 2015 22

Hospital Acquired Pneumonia (HAP)-Pipeline by AstraZeneca PLC, H1 2015 23

Hospital Acquired Pneumonia (HAP)-Pipeline by Cardeas Pharma Corp., H1 2015 24

Hospital Acquired Pneumonia (HAP)-Pipeline by Cubist Pharmaceuticals, Inc., H1 2015 25

Hospital Acquired Pneumonia (HAP)-Pipeline by Dong-A Socio Group, H1 2015 26

Hospital Acquired Pneumonia (HAP)-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 27

Hospital Acquired Pneumonia (HAP)-Pipeline by KaloBios Pharmaceuticals, Inc., H1 2015 28

Hospital Acquired Pneumonia (HAP)-Pipeline by MedImmune, LLC, H1 2015 29

Hospital Acquired Pneumonia (HAP)-Pipeline by Meiji Seika Pharma Co., Ltd., H1 2015 30

Hospital Acquired Pneumonia (HAP)-Pipeline by Melinta Therapeutics, Inc, H1 2015 31

Hospital Acquired Pneumonia (HAP)-Pipeline by Nabriva Therapeutics AG, H1 2015 32

Hospital Acquired Pneumonia (HAP)-Pipeline by Savara Inc., H1 2015 33

Hospital Acquired Pneumonia (HAP)-Pipeline by Serendex Pharmaceuticals A/S, H1 2015 34

Hospital Acquired Pneumonia (HAP)-Pipeline by Tetraphase Pharmaceuticals Inc., H1 2015 35

Assessment by Monotherapy Products, H1 2015 36

Assessment by Combination Products, H1 2015 37

Number of Products by Stage and Target, H1 2015 39

Number of Products by Stage and Mechanism of Action, H1 2015 41

Number of Products by Stage and Route of Administration, H1 2015 43

Number of Products by Stage and Molecule Type, H1 2015 45

Hospital Acquired Pneumonia (HAP) Therapeutics-Recent Pipeline Updates, H1 2015 81

Hospital Acquired Pneumonia (HAP)-Dormant Projects, H1 2015 105

Hospital Acquired Pneumonia (HAP)-Discontinued Products, H1 2015 106

List of Figures

Number of Products under Development for Hospital Acquired Pneumonia (HAP), H1 2015 9

Number of Products under Development for Hospital Acquired Pneumonia (HAP)-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Comparative Analysis by Clinical Stage Development, H1 2015 15

Comparative Analysis by Early Stage Products, H1 2015 16

Assessment by Monotherapy Products, H1 2015 36

Assessment by Combination Products, H1 2015 37

Number of Products by Top 10 Targets, H1 2015 38

Number of Products by Stage and Top 10 Targets, H1 2015 38

Number of Products by Top 10 Mechanism of Actions, H1 2015 40

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 40

Number of Products by Top 10 Routes of Administration, H1 2015 42

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 42

Number of Products by Top 10 Molecule Types, H1 2015 44

Number of Products by Stage and Top 10 Molecule Types, H1 2015 44

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Achaogen Inc.

Adenium Biotech ApS

AstraZeneca PLC

Cardeas Pharma Corp.

Cubist Pharmaceuticals, Inc.

Dong-A Socio Group

F. Hoffmann-La Roche Ltd.

KaloBios Pharmaceuticals, Inc.

MedImmune, LLC

Meiji Seika Pharma Co., Ltd.

Melinta Therapeutics, Inc

Nabriva Therapeutics AG

Savara Inc.

Serendex Pharmaceuticals A/S

Tetraphase Pharmaceuticals Inc.

Hospital Acquired Pneumonia (HAP) Therapeutic Products under Development, Key Players in Hospital Acquired Pneumonia (HAP) Therapeutics, Hospital Acquired Pneumonia (HAP) Pipeline Overview, Hospital Acquired Pneumonia (HAP) Pipeline, Hospital Acquired Pneumonia (HAP) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com